Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin

Treatment of hepatitis C virus with telaprevir (VX-950) in patients non-responsive to treatment with pegylated interferon-alpha 2A/2B and ribavirin

US Patent 8664273 · Granted Mar 4, 2014

Estimated economic value: $101,650,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of treating hepatitis E viral infection2019
Genetic markers associated with interferon-alpha response2013
Dose forms2013